

GSK126

Catalog No: tcsc1401



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

1346574-57-9

Formula:

$C_{31}H_{38}N_6O_2$

Pathway:

Epigenetics;Epigenetics

Target:

Histone Methyltransferase;Epigenetic Reader Domain

Purity / Grade:

>98%

Solubility:

DMSO : 13.5 mg/mL (25.63 mM; Need ultrasonic)

Alternative Names:

EZH2 inhibitor;GSK2816126A

Observed Molecular Weight:

526.67


Product Description

GSK126 is a potent, highly selective inhibitor of **EZH2 methyltransferase** activity with **IC₅₀** of 9.9 nM.

IC50 & Target: IC50: 9.9 nM (EZH2)^[1]

In Vitro: GSK126 potently inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies ($K_i=0.5-3$ nM) independent of substrate used, and is competitive with S-adenosyl-methionine (SAM) and non-competitive with peptide substrates. GSK126 is highly selective against other methyltransferases and multiple other protein classes (EZH1, $IC_{50}=680$ nM)^[1]. Treatment of three SCLC cell lines with GSK126, induces growth inhibition. SCLC cell lines (Lu130, H209, and DMS53) are treated with 0.5, 2, and 8 μ M GSK126, and growth curve is analyzed by WST-8 assay. Inhibition of cellular growth by GSK126 treatment is observed at 8 μ M in all the three cell lines, while Lu130 and H209 are more sensitive to GSK126, even at lower doses^[2].

In Vivo: GSK126 is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight in female beige SCID mice. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!